유도만능줄기세포(iPS 세포) 시장 : 시장 규모, 동향 및 예측(2026년)

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and clinical trials employing human iPSC-derived cell types have been undertaken. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:

• Cellular Therapy: iPSCs are being investigated for use in a wide range of cell therapy applications aimed at reversing injuries or curing diseases by replacing damaged or lost cells.
• Disease Modeling: iPSCs derived from patients with specific disorders can be differentiated into disease-specific cell types, enabling the creation of accurate, functional disease models "in a dish" for research and therapeutic development.
• Drug Development and Discovery: iPSCs provide physiologically relevant cells for drug discovery processes, including compound identification, target validation, compound screening, and tool development, significantly improving the efficiency and relevance of these efforts.
• Personalized Medicine: By combining iPSCs with genome-editing technologies like CRISPR, scientists can introduce precise genetic modifications, such as knock-outs, knock-ins, or single base changes, paving the way for customized treatments tailored to individual genetic profiles.
• Toxicology Testing: iPSCs or their derivatives (tissue-specific cells) are used for toxicology screening to assess the safety and efficacy of compounds or drugs in living cells, reducing reliance on animal testing.
• Tissue Engineering: iPSCs can be cultured on biocompatible scaffolds that mimic the structure and properties of target tissues, providing a supportive environment for cell growth and differentiation and aiding the development of engineered tissues for transplantation.
• Organoid Production: iPSCs can self-organize into 3D structures called organoids, which closely resemble the structure and function of human organs. Organoids are valuable for studying organ development, modeling diseases, and testing drug candidates.
• Gene Editing: iPSCs can be modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic alterations. These edited iPSCs can then be differentiated into functional cells for transplantation or advanced disease studies.
• Research Tools: iPSCs and their derivatives are extensively used in both basic and applied research to study cellular processes, understand diseases, and test experimental therapies.
• Stem Cell Banking: iPSC repositories store and provide access to diverse iPSC-derived cell types, offering researchers valuable resources to investigate conditions using cells from both healthy and affected donors.
• Cultured Meat Production: iPSCs are utilized in lab-grown meat production, serving as a cellular foundation for creating clean, sustainable meat products without the need for traditional animal farming.
• 3D Bioprinting: iPSCs can be differentiated into specific cell types, such as skin, heart, or liver cells, and incorporated into bioinks for use in 3D bioprinting applications, enabling the creation of complex tissue structures.

iPSC Market Dynamics

Since the discovery of iPSCs approximately 18 years ago, the field has advanced at an unprecedented pace. It took just seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been increasingly used in preclinical studies, physician-led research, and clinical trials worldwide, underscoring their transformative potential.

The discovery of iPSCs has revolutionized several scientific fields, including drug discovery, toxicity testing, and in-a-dish disease modeling, while also having a profound impact on cell and gene therapy. Their ability to multiply indefinitely in vitro and differentiate into specialized cells has made them a highly versatile and ideal source for clinical cell replacement therapies and advanced disease modeling.

The first cellular therapy involving iPSCs began in 2013 at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, this trial investigated the safety of iPSC-derived retinal cell sheets in patients with macular degeneration. In 2016, Cynata Therapeutics achieved a world first by gaining approval for a clinical trial of an allogeneic iPSC-derived cell product, CYP-001, for treating steroid-resistant acute graft-versus-host disease (GvHD). This iPSC-derived mesenchymal stem cell (MSC) product demonstrated positive safety and efficacy results, successfully meeting its clinical endpoints.

Today, iPSCs are at the center of at least 228 ongoing clinical trials targeting a range of conditions. iPSC-derived MSCs are being tested for steroid-resistant acute GvHD, while dopaminergic progenitors derived from iPSCs are being evaluated for Parkinson’s disease. In oncology, iPSC-derived natural killer (iNK) cells are being studied as cancer immunotherapies for metastatic solid tumors. Other applications include the use of retinal pigment epithelial cells for age-related macular degeneration (AMD) and insulin-secreting beta cells derived from iPSCs for Type 1 diabetes. These diverse therapeutic programs highlight the vast potential of iPSCs in treating a variety of diseases.

Of the 228 total trials, 66 are specifically evaluating iPSC-derived cells as therapeutics - the rest are non-therapeutic, such as disease modeling a research use - with a focus on regenerative medicine applications like Parkinson's disease, retinal diseases, heart failure, and immune disorders, mostly in Phase I/II.

The iPS cell sector has seen steady M&A activity in recent years, including Axol Biosciences' acquisitions of Newcells Biotech and Phenocell, and Century Therapeutics' $35 million acquisition of Clade Therapeutics, alongside a wave of strategic partnerships and licensing deals aimed at scaling GMP-compliant manufacturing and advancing off-the-shelf allogeneic cell therapies. Venture capital investment has remained strong, totaling roughly $1.04 billion between 2023 and April 2026, down from a 2021 peak of $2.15 billion, as investors increasingly favor companies with proprietary, full-stack manufacturing platforms poised to move from research into clinical-stage therapeutics.

The commercial potential of iPSCs has also expanded significantly. Companies are leveraging iPSC-derived products in drug development, disease modeling, and toxicology testing. FUJIFILM Cellular Dynamics International (FCDI) stands out as one of the largest players in the field. Cellular Dynamics International (CDI), founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, became one of the first companies to derive human iPSC lines in 2007. In 2015, FUJIFILM acquired CDI for $307 million, creating FCDI, which is now the world’s largest producer of human cells derived from iPSCs for research and regenerative medicine.

ReproCELL, founded in 2009 as a venture from the University of Tokyo and Kyoto University, was the first company to commercialize iPSC products. Its ReproCardio line of iPSC-derived cardiomyocytes paved the way for the industry. In Europe, leading competitors include Evotec and Ncardia. Evotec, based in Hamburg, Germany, has built one of the most advanced iPSC platforms in the world, focusing on industrializing iPSC-based drug screening. Ncardia, formed through the merger of Axiogenesis and Pluriomics in 2017, specializes in cardiac and neural applications of iPSCs. Axiogenesis, one of its predecessors, was the first European company to license iPSC technology in 2010.

Large research supply companies are also playing a major role in the commercialization of iPSC-derived products. These include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and numerous others. Collectively, more than 90 companies are active in the iPSC market, offering a broad range of products, services, and technologies that cater to both research and therapeutic applications.

The global iPSC market continues to grow rapidly. A comprehensive report on the field provides an overview of key players, strategic partnerships, and innovations driving the sector. The report explores the current status of iPSC research, manufacturing technologies, and clinical developments. It highlights the rates of iPSC-related patents, publications, and trials, detailing all known therapeutic programs involving iPSC-derived cells. Additionally, the report covers the funding landscape, examining fundraising efforts, IPOs, and co-development agreements that are shaping the market’s trajectory.

The report also delves into the expanding use of iPSCs in drug discovery and the strategic partnerships that are driving growth in this sector. It presents a detailed breakdown of market size by application, technology, cell type, and geography (North America, Europe, Asia-Pacific, and the rest of the world). Total market size figures, along with projected growth rates through 2034, provide insights into the future of the iPSC industry.

With their remarkable versatility, iPSCs are set to redefine medicine and biotechnology. From disease modeling and drug discovery to advanced cell replacement therapies, iPSCs are driving innovation at every level. As companies continue to refine manufacturing technologies and expand therapeutic applications, the future of iPSCs holds immense promise for transforming healthcare and scientific research.

About the Publisher

With an online readership of nearly one million viewers per year, the publisher is a U.S. market research firm founded in 2006 that has over 20+ years of experience in tracking stem cell markets. As the first and only market research firm to specialize in the stem cell industry, the publisher’s research has been cited by the Wall Street Journal and Vogue Magazine, as well as quoted in Tony Robbin’s best-selling book, Life Force. Founded in 2006 and headquartered in Washington, DC, the publisher is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, the publisher has unparalleled access to key opinion leaders (KOLs) from across the global iPSC market.

Table of Contents

1. REPORT OVERVIEW

• 1.1 Statement of the Report

2. INTRODUCTION

3. CURRENT STATUS OF IPSC INDUSTRY

• 3.1 Approval of the First Two iPSC-based Therapies
  • 3.1.1 Amchepry (raguneprocel)
  • 3.1.2 ReHeart
• 3.2 Forthcoming iPSC-Derived Therapeutics
  • 3.2.1 Fertilo
  • 3.2.2 Bemdaneprocel (BRTX-100)
• 3.3 The Second Line of iPSC-based Products in Clinical Trials
• 3.4 Current Status of iPSC-Based Clinical Trials for Therapeutic Development
• 3.5 AI-Powered Automation in iPSC Manufacturing
  • 3.5.1 Companies Providing AI-Powered Automation Services
• 3.6 Advanced Reprogramming Technologies Currently in use
  • 3.6.1 The Major Patent Cliff beginning in
    • 3.6.1.1 The New “Post-Expiry” Opportunities
• 3.7 Shift toward Automation in iPSC Production
• 3.8 Current Utilization of Genome-Editing Tools in iPSCs
• 3.9 Current Utilization of Organoids & 3D Tissues in iPSC-Derived Disease Models
• 3.10 Significant increase in the number of Market Participants
  • 3.10.1 Types of iPSC-Related Companies in
    • 3.10.1.1 The iPSC Therapeutics Developers (Clinical & Preclinical) Companies
    • 3.10.1.2 iPSC Product & Research Tool Suppliers
    • 3.10.1.3 Contract Development and Manufacturing Organizations (CDMOs)
    • 3.10.1.4 Longevity and Rejuvenation Companies (Partial Reprogramming)

4. IPSC MANUFACTURING

• 4.1 Tissue Acquisition and Donor Screening
• 4.2 Somatic Cell Isolation and Priming
  • 4.2.1 Isolation of Dermal Fibroblasts
• 4.3 Reprogramming of Somatic Cells into iPSCs
• 4.4 Expansion and Selection of iPSC Colonies
  • 4.4.1 Selection of iPSC Colonies after Reprogramming
• 4.5 Directed Differentiation of iPSCs into Specific Cell Types
• 4.6 Development of Organoids from iPSCs
  • 4.6.1 Key Steps in iPSC-Derived Organoid Development

5. RESEARCH PUBLICATIONS ON INDUCED PLURIPOTENT STEM CELLS

• 5.1 Rapid Growth of iPSC Publications in PubMed.gov
• 5.2 Categories of iPSC Research Themes
  • 5.2.1 PubMed Published iPSC Papers on Pathophysiological Studies
  • 5.2.2 PubMed Published iPSC Papers on Reprogramming Studies
  • 5.2.3 PubMed Published Papers on iPSC Differentiation Studies
  • 5.2.4 PubMed Published Papers on iPSC-based Drug Discovery
  • 5.2.5 PubMed Published Papers on iPSC-based Cell Therapy
  • 5.2.6 Future Trends in iPSC Research
    • 5.2.6.1 Anticipated advancements in Therapeutic Applications
    • 5.2.6.2 Enhanced Disease Modeling and Drug discovery
    • 5.2.6.3 Technological Innovations and Automation
    • 5.2.6.4 Future Research Directions and Challenges

6. IPSC PATENT LANDSCAPE

• 6.1 iPSC Patent Applications by Jurisdiction
• 6.2 iPSC Patent Applicants
• 6.3 Inventors of iPSC Patent Applications
• 6.4 Major iPSC Patent Owners
• 6.5 Current Legal Status of iPSC Patents
  • 6.5.1 Granted iPSC Patents
  • 6.5.2 Key Technology Areas Protected
  • 6.5.3 Geographical Trends in iPSC Granted Patents
  • 6.5.4 Recently Granted iPSC Patents (2024-2026)
    • 6.5.4.1 Recent Patent of RxCell, Inc.
    • 6.5.4.2 Recent Patent of Pluristyx
    • 6.5.4.3 Recent Patent of Applied StemCell, Inc.
    • 6.5.4.4 Recent Patent of iPS Academia Japan/Kyoto University
    • 6.5.4.5 Recent Patent of Allele Biotechnology
• 6.6 Recent iPSC Patent Licensing Activity
  • 6.6.1 Licensing Fees for iPSC Patents
• 6.7 The Future Direction of Growth in iPSC Patent Activity
  • 6.7.1 The “Patent Cliff” and Focus Shift

7. CLINICAL TRIAL LANDSCAPE: INDUCED PLURIPOTENT STEM CELLS

• 7.1 Late-Stage iPSC Clinical Trials & Progress
• 7.2 Current Recruitment Status
• 7.3 iPSC Clinical Trials by Study Designs
• 7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials
  • 7.4.1 The iPSC Non-Therapeutic Clinical Studies by Use
  • 7.4.2 Diseases Targeted by Therapeutic Studies
  • 7.4.3 The iPSC Clinical Trials Addressing Ocular Diseases
  • 7.4.4 Trials IPSC-Based Clinical Trials Addressing CNS Disorders
  • 7.4.5 IPSC-Derived Cardiomyocytes and Muscle Products in Clinical Trials
  • 7.4.6 IPSC-Based in Immune and Blood Products Clinical Trials
  • 7.4.7 Stromal Products in Clinical Trials
• 7.5 iPSC-based Clinical Trials by Phase of Study
• 7.6 iPSC Clinical Trials by Funder Type
• 7.7 Geographic Distribution of iPSC Clinical Trials
• 7.8 Predicted Future Directions of iPSC-Based Clinical Trials

8. M&A, COLLABORATIONS AND FUNDING ACTIVITIES IN IPSC SECTOR

• 8.1 Mergers and Acquisitions (M&A) in iPSC Sector
  • 8.1.1 Axol Biosciences’ Acquisition of Newcells Biotech
  • 8.1.2 Acquisition of Phenocell by Axol Biosciences
  • 8.1.3 Acquisition of Clade Therapeutics by Century Therapeutics
• 8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector
  • 8.2.1 Cartherics & Catalent
  • 8.2.2 Applied StemCell, Inc. & Cellipont Bioservices
  • 8.2.3 GelMEDIX & Catalent
  • 8.2.4 ISCT & JSRM
  • 8.2.5 SmartCella Holding & Catalent
  • 8.2.6 Mytos & Pluristyx
  • 8.2.7 Cell X Technologies & BioLamina
  • 8.2.8 Pluristyx & Solesis
  • 8.2.9 Pluristyx & BioLamia
  • 8.2.10 Celaid Therapeutics & AGC
  • 8.2.11 Cellino & Karis Bio
  • 8.2.12 Ginkgo Bioworks & Universal Cells
  • 8.2.13 BrightPath Bio & Cellistic
  • 8.2.14 Alloy Therapeutics & Takeda
  • 8.2.15 Factor Bioscience & Eterna Therapeutics
  • 8.2.16 Aspen Neuroscience & Cell X Technologies
  • 8.2.17 Shinobi Therapeutics & Panasonic
  • 8.2.18 SCG Cell Therapy and A*STAR
  • 8.2.19 Charles River Laboratories & Pluristyx
  • 8.2.20 Pluristyx & National Resilience, Inc
  • 8.2.21 University of Texas & GeneCure
  • 8.2.22 BlueRock Therapeutics & Bit.bio
  • 8.2.23 Applied Stem Cell, Inc. & CIRM
• 8.3 Venture Capital Funding in iPSC Sector
  • 8.3.1 Trailhead Biosystems, Inc.
  • 8.3.2 Morphocell Technologies, Inc.
  • 8.3.3 Aspen Neuroscience, Inc.
  • 8.3.4 Celaid Therapeutics, Inc.
  • 8.3.5 GC Therapeutics, Inc.
  • 8.3.6 iRegene Therapeutics
  • 8.3.7 Gameto
  • 8.3.8 Pluristyx
  • 8.3.9 Asgard Therapeutics
  • 8.3.10 Kenai Therapeutics
  • 8.3.11 Pluristyx
  • 8.3.12 Fujifilm Cellular Dynamics
  • 8.3.13 Mogrify, Ltd.
  • 8.3.14 Heartseed, Inc.
  • 8.3.15 Elevate Bio

9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)

• 9.1 Reprogramming Factors (OSKM Cocktail/Yamanaka Factors)
  • 9.1.1 Roles of OSKM Factors in the Induction of iPSCs
  • 9.1.2 Companies offering Reprogramming Services
• 9.2 Direct Reprogramming
  • 9.2.1 Companies offering Direct Reprogramming Services
• 9.3 Delivery of Reprogramming Factors
  • 9.3.1 Currently Favored Reprogramming Factors
    • 9.3.1.1 Sendai Virus (SeV) Reprogramming (Gold Standard)
    • 9.3.1.2 mRNA-Based Reprogramming (High Safety)
    • 9.3.1.3 Episomal Plasmid Vectors (Simplicity)
    • 9.3.1.4 Comparative Efficacies of Reprogramming Methods
• 9.4 Genome Editing Technologies in iPSC Generation
  • 9.4.1 Companies offering CRISPR/Cas9 Services for iPSC Generation
• 9.5 Development of iPSC-Derived Organoids
  • 9.5.1 Companies Developing iPSC-Derived Organoids
• 9.6 Development of iPSC-Derived Cardiac Tissue Sheets
• 9.7 Development of iPSC-Derived RPE Sheets
• 10.1 EBiSC
  • 10.1.1 IPSCs Available with EBiSC
• 10.2 RIKEN BRC
  • 10.2.1 The iPSC Lines available with RIKEN BRC
• 10.3 CiRA
• 10.4 WiCell
• 10.5 HipSci
• 10.6 hPSCreg
• 10.7 inStem
• 10.8 Coriell Institute for Medical Research
  • 10.8.1 Cell Lines offered by Coriell
• 10.9 Cost Difference for iPSC Lines between Non-Profit Banks and Commercial Providers
• 10.10 Cell Sources & Reprogramming Methods in iPSC Banks
• 10.11 Ownership and Funding for iPSC Banks
• 11.1 Applications of iPSCs in Basic Research
  • 11.1.1 Consumption of iPSC lines in Research
  • 11.1.2 Providers of iPSC Research Products for Researchers
  • 11.1.3 Product Categories used in iPSC Research
    • 11.1.3.1 The iPSC Reprogramming Kits
    • 11.1.3.2 Culture Media & Reagents used in Research
    • 11.1.3.3 Differentiated iPS Cells used in Research
    • 11.1.3.4 3D Organoids from iPSCs for Research
    • 11.1.3.5 Specialized Services in iPSC Manufacturing
    • 11.1.3.6 Procurement of iPSC-based Research Products by Researchers
      • 11.1.3.6.1 Procurement from Commercial Suppliers
      • 11.1.3.6.2 Procurement from Public and Private Repositories
      • 11.1.3.6.3 Direct Generation/Custom Services
• 11.2 Applications of iPSCs in Drug Discovery
  • 11.2.1 Applications of iPSCs in Patient-Specific Disease Modeling
    • 11.2.1.1 Companies offering iPSC-Derived Cardiomyocytes for Drug Discovery
      • 11.2.1.1.1 Drugs Tested for Cardiovascular Diseases using iPSCs
    • 11.2.1.2 Companies offering iPSC-derived Neuronal Cells for Drug Discovery
      • 11.2.1.2.1 Drugs Tested for Neurological Diseases using iPSCs
    • 11.2.1.3 Companies offering iPSC-Derived RPEs
      • 11.2.1.3.1 Drugs Tested for Ocular Diseases using iPSC Lines
    • 11.2.1.4 Companies developing iPSCs to Discover Drugs for Metabolic Diseases
      • 11.2.1.4.1 Drugs Tested in iPSCs for Metabolic Diseases
    • 11.2.1.5 Companies Developing iPSCs to Discover Drugs for Blood Disorders
      • 11.2.1.5.1 Drugs Tested for Blood Disorders using iPSCs
    • 11.2.1.6 The iPSCs in High-Throughput Screening (HTS)
    • 11.2.1.7 The iPSCs in Drug Toxicity and Safety Assessment
      • 11.2.1.7.1 Companies offering Toxicity Testing Services using iPSC-Derived Cells
      • 11.2.1.7.2 Drugs Tested for their Toxicity using iPSC Lines
      • 11.2.1.7.3 Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies
    • 11.2.1.8 The iPSCs in Personalized Medicine and Genomic Studies
  • 11.2.3 Applications of iPSC-Derived Cells in Cell Therapies (Regenerative Medicine)
    • 11.2.3.1 Companies developing iPSC-based Cell Therapies
    • 11.2.3.2 The Landscape of iPSC-Based Cell Therapy Clinical Trials
      • 11.2.3.2.1 Key Therapeutic Targets in iPSC-Based Cell Therapy Clinical Trials
      • 11.2.3.2.2 iPSC-Based Cell Therapy Clinical Trials
  • 11.2.4 Other Novel Applications of iPSCs
    • 11.2.4.1 Bioinks for Tissue Engineering
      • 11.2.4.1.1 Companies developing iPSC-Based Bioinks
    • 11.2.4.2 The iPSCs in the Conservation of Endangered Species
      • 11.2.4.2.1 Key Applications of iPSCs Conservation
      • 11.2.4.2.2 Major Conservation Programs using iPSCs
      • 11.2.4.2.3 Development of iPSCs from Domestic & Wild Animals
    • 11.2.4.3 Cultured Meat Production using iPSCs
      • 11.2.4.3.1 Companies Developing Cultured Meat using iPSCs
• 11.3 Cost of iPSC-Based Products & Services
• 12.1 Global Market for Induced Pluripotent Stem Cells (iPSCs) by Geography
• 12.2 Global Market for iPSCs by Market Segments
• 12.3 Global Market for iPSC-based Reprogramming Technologies
• 12.4 Global Market for iPSC-Derived Cell Types
• 12.5 Global Market for Manual & Automated iPSC Production Services
  • 12.5.1 Market Share for Key Modules in iPSC Production
  • 12.5.2 Market Shares of Products Utilized in iPSC Manufacturing
  • 12.5.3 Percent Market Share of iPSC-Derived Cells by End-Use,
• 12.6 Key iPSC Market Drivers
• 12.7: Key iPSC Market Restraints
• 12.8 Predicted Shifts in iPSC market
  • 12.8.1 Shift from Research to Clinical Applications
  • 12.8.2 Technological Shifts in Production and Quality
  • 12.8.3 Application & Therapeutic Shifts
  • 12.8.4 Regional & Strategic Shifts
• 13.1 28bio
  • 13.1.1 The Nexon™ platform
  • 13.1.2 CNS-3D Technology
  • 13.1.3 CNS-3D Organoid Services
  • 13.1.4 PNS-3D Organoids
  • 13.1.5 PNS-3D Organoid Services
• 13.2 AcceGen
  • 13.2.1 Treatments for Neurodegenerative Diseases with iPSCs
  • 13.2.2 AcceGen’s Pipeline
• 13.3 Accellta, Ltd.
  • 13.3.1 Accellta’s Foodtech
  • 13.3.2 Accellta’s Biotech Services
  • 13.3.3 Accellta’s Core Technology
• 13.4 Alder Therapeutics
• 13.5 Aldevron
  • 13.5.1 Key Products and Services for iPSC
• 13.6 Allele Biotechnology
  • 13.6.1 mRNA Reprogramming
  • 13.6.2 mRNA Differentiation
• 13.7 Altos Labs
• 13.8 Applied StemCell, Inc. (ASC)
  • 13.8.1 Genome Editing Platforms
  • 13.8.2 The iPSC Drug Discovery Platform
  • 13.8.3 The iPSC Gene Editing Services
  • 13.8.4 The iPSC Differentiation Services
  • 13.8.5 The iPSC Generation Services
  • 13.8.6 Product Offerings
• 13.9 Arktus Therapeutics, Co., Ltd.
  • 13.9.1 Technologies
• 13.10 Aspen Neuroscience
  • 13.10.1 Autologous Manufacturing Process
  • 13.10.2 Aspen’s Clinical Pipeline
• 13.11 ATCC
  • 13.11.1 Product Offerings
• 13.12 Axxam S.p.A.
  • 13.12.1 The iPSC Platform Capabilities
• 13.13 Axol Bioscience
  • 13.13.1 Products
  • 13.13.2 Services
  • 13.13.3 iPSC-derived Models
• 13.14 BD Biosciences
  • 13.14.1 Key Contributions and Tools
• 13.15 Bit.bio
  • 13.15.1 Products & Services
    • 13.15.1.1 Human iPSC-derived glial cells
• 13.16 BlueRock Therapeutics
  • 13.16.1 BlueRock’s Cell Therapy Programs
    • 13.16.1.1 Neurology Program
    • 13.16.1.2 Ophthalmology Program
• 13.17 BPS Bioscience
  • 13.17.1 Product Offerings
• 13.18 BrainXell
  • 13.18.1 Product Offerings
  • 13.18.2 Services Offered
• 13.19 BrainZell
  • 13.19.1 Technology
  • 13.19.2 Selection of Source Cells
• 13.20 BrightPath Biotherapeutics Co., Ltd.
• 13.21 Cartherics Pty Ltd
  • 13.21.1 CTH-401
  • 13.21.2 CTH-004
• 13.22 Catalent, Inc.
  • 13.22.1 Services
• 13.23 Celogics
  • 13.23.1 Custom Cardiomyocytes
• 13.24 Celregen Therapeutics
  • 13.24.1 Core Platform Technologies
  • 13.24.2 Key iPSC Product Candidates
• 13.25 Cellectis
  • 13.25.1 TALEN® Technology
  • 13.25.2 PulseAgile Technology
• 13.26 CellGenix GmbH
  • 13.26.1 Key Contributions
• 13.27 Cellistic
  • 13.27.1 CDMO Services
  • 13.27.2 Allo Chassis™ Platform
  • 13.27.3 STAR-CRISPR™ Technology
  • 13.27.4 Pulse Cell Line Development Platform
  • 13.27.5 Cellistic’s Echo Manufacturing Platform
  • 13.27.6 GMP Manufacturing
  • 13.27.7 ECHO™-NK Platform
  • 13.27.8 Echo™-Cardio platform
  • 13.27.9 Echo™-Endothelial Platform
  • 13.27.10 Echo™-T Platform
• 13.28 CellSystems GmbH
  • 13.28.1 Core Competencies in iPSC Technology
• 13.29 Cellusion, Inc.
  • 13.29.1 CECSI Cells
• 13.30 Celregen Therapeutics
  • 13.30.1 Products in Development
    • 13.30.1.1 Islet Cells
    • 13.30.1.2 The iCEnCs
• 13.31 Century Therapeutics
  • 13.31.1 Century’s Approach
  • 13.31.2 Century’s Precision Gene Editing Technology
    • 13.31.2.1 Allo-Evasion™ Technology
  • 13.31.3 Century’s Pipeline Overview
• 13.32 Citius Pharmaceuticals, Inc.
  • 13.32.1 Induced Mesenchymal Stem Cells (i-MSCs)
• 13.33 clock.bio
  • 13.33.1 The clock.bio’s Platform
    • 13.33.1.1 The geneAge Atlas of Aging and Rejuvenation Genes
    • 13.33.1.2 The imAge
    • 13.33.1.3 The clinAge Platform
• 13.34 Creative Medical Technology Holdings, Inc.
  • 13.34.1 The iPSCelz® Program
• 13.35 CUORiPS, Inc
  • 13.35.1 Conditional Approval for ReHeart in Japan
    • 13.35.1.1 Treatment Modality for ReHeart
• 13.36 Curi Bio, Inc.
  • 13.36.1 Curi Bio’s Biosystem Platforms
  • 13.36.2 3D Engineered Models
  • 13.36.3 The Curi Engine™: Custom Services
• 13.37 Cynata Therapeutics
  • 13.37.1 Cymerus™ Technology
  • 13.37.2 Clinical Development
• 13.38 CytoMed Therapeutics Limited
  • 13.38.1 iPSC-γδ NKT Cell Technology
• 13.39 Defined Bioscience, Inc.
  • 13.39.1 Products for Disease Modeling
• 13.40 Editas Medicine
  • 13.40.1 Edita’s iPSC Platform
• 13.41 EditCo Bio, Inc.
  • 13.41.1 Services
  • 13.41.2 CRISPR Reagents & Kits
• 13.42 ErneXa Therapeutics
• 13.43 Esco Lifesciences
  • 13.43.1 Key Contributions
• 13.44 Evotec
  • 13.44.1 Services
• 13.45 Eyestem Research Pvt. Ltd.
  • 13.45.1 Eyecyte-RPE™
  • 13.45.2 Eyecyte-PRPTM
  • 13.45.3 AAV mediated gene augmentation
• 13.46 Factor Biosynthesis, Inc.
  • 13.46.1 The mRNA Reprogramming Technology Platforms
  • 13.46.2 UltraSlice™ Gene Editing Technology Platforms
• 13.47 Fate Therapeutics, Inc.
  • 13.47.1 Fate Therapeutics’ iPSCs Platform
  • 13.47.2 Fate Therapeutics’ Pipeline Overview
• 13.48 FUJIFILM Cellular Dynamics
  • 13.48.1 Products
  • 13.48.2 Custom Services
  • 13.48.3 The iPSC CDMO Services
• 13.49 Gameto, Inc.
  • 13.49.1 Gameto’s Science
    • 13.49.1.1 Fertilo
    • 13.49.1.2 Ameno
    • 13.49.1.3 Deovo
• 13.50 GC Therapeutics
  • 13.50.1 TFome™ Platform
• 13.51 GenScript
  • 13.51.1 iPSC-Related Services
  • 13.51.2 iPSC-Related Products
• 13.52 GOLIVER THERAPEUTICS
  • 13.52.1 GOLIVER Solution
• 13.53 Greenstone Biosciences
  • 13.53.1 Products
  • 13.53.2 Services
• 13.54 Healios K.K.
• 13.55 HeartBeat.bio AG
  • 13.55.1 Cardioids (Cardiac Organoids)
    • 13.55.1.1 Cardioid Drug Discovery Platform
  • 13.55.2 Disease Models
  • 13.55.3 Assays
  • 13.55.4 Drug Discovery Strategy
• 13.56 Heartseed, Inc.
  • 13.56.1 Remuscularization Technology
  • 13.56.2 Cardiomyocyte Spheroid
• 13.57 Hebecell Corporation
  • 13.57.1 ProtoNK™
  • 13.57.2 Contract Manufacturing Services
• 13.58 HELP Therapeutics
• 13.59 Herophilus
  • 13.59.1 Herophilus’ Approach
• 13.60 Hesperos, Inc.
  • 13.60.1 Human-on-a-Chip®
• 13.61 Horizon Discovery
• 13.62 HUB Organoids BV
  • 13.62.1 Products
• 13.63 iCamuno Biotherapeutics
  • 13.63.1 Transient Naive Treatment (TNT)
• 13.64 iHeart Japan Corporation
  • 13.64.1 Contract Services
• 13.65 IN8Bio
  • 13.65.1 INB-500
• 13.66 InSphero
  • 13.66.1 Products & Services
• 13.67 iPeace, Inc.
  • 13.67.1 Products
  • 13.67.2 Manufacturing Service
• 13.68 iPS Academia Japan, Inc.
  • 13.68.1 Key Aspects of iPS Academia Japan, Inc.
• 13.69 IPS HEART
  • 13.69.1 Proprietary Platform
    • 13.69.1.1 ISX9-CPC
    • 13.69.1.2 GIVI-MPC
• 13.70 iPSirius
  • 13.70.1 iPVAC Technology
  • 13.70.2 iPSirius’ Pipeline
• 13.71 iRegene Therapeutics
  • 13.71.1 iReDita Platform
• 13.72 iXCells Biotechnologies
  • 13.72.1 iXCells’ Core Services
  • 13.72.2 Products
    • 13.72.2.1 Organoids
• 13.73 iXgene, Inc.
  • 13.73.1 Technology
• 13.74 Jacobio Pharmaceuticals
  • 13.74.1 Jacobio’s iPSC Collaboration with Hebecell
• 13.75 Kangstem Biotech
• 13.76 Kenai Therapeutics
  • 13.76.1 Kenai’s iPSC Platform
  • 13.76.2 Kenai’s Pipeline
• 13.77 Khloris Biosciences, Inc.
• 13.78 Kiji Therapeutics
• 13.79 Lambda Biologics GmbH
  • 13.79.1 Organoid Services
• 13.80 Laverock Therapeutics
  • 13.80.1 iPSC-derived Cell Therapies
• 13.81 Lineage Cell Therapeutics
• 13.82 Lonza
  • 13.82.1 Key Contributions
• 13.83 Megakaryon Corporation
  • 13.83.1 Technology
  • 13.83.2 Megakaryons R&D Pipeline
• 13.84 Miltenyi Biotec, Inc.
  • 13.84.1 Tools for Manual iPSC Workflows
  • 13.84.2 Automated and Closed iPSC Manufacturing
• 13.85 Morphocell Technologies, Inc.
  • 13.85.1 ReLiver
• 13.86 Myoridge Co. Ltd.
  • 13.86.1 Products & Services
• 13.87 Ncardia
  • 13.87.1 Products
  • 13.87.2 Services
• 13.88 NeuCyte, Inc.
  • 13.88.1 Technology
  • 13.88.2 NeuCyte’s Services
• 13.89 Neukio Biotherapeutics
• 13.90 NEXEL
  • 13.90.1 Organoids
  • 13.90.2 iPSC Derived Cells
  • 13.90.3 Instruments
  • 13.90.4 NeXST (Next Xight Screening Test)
  • 13.90.5 Disease Modeling
  • 13.90.6 Cell Customization
  • 13.90.7 Services
• 13.91 Okomera
  • 13.91.1 Ocentra
• 13.92 Organovo Holdings, Inc.
  • 13.92.1 Product Pipeline
• 13.93 Orizuru Therapeutics
• 13.94 Oxford StemTech
  • 13.94.1 Services Offered
• 13.95 Parallel Bio
• 13.96 Pixl Bio, Ltd.
  • 13.96.1 Platform
  • 13.96.2 Products
    • 13.96.2.1 The pixStellate iPSC-derived Stellate Cells
    • 13.96.2.2 pixHep/pixStellate Co-Culture Models
    • 13.96.2.3 MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Models
    • 13.96.2.4 The pixHep A1ATD (Alpha-1 Antitrypsin Deficiency) Models
    • 13.96.2.5 The pixHep PFIC2 (Progressive Familial Intrahepatic Cholestasis Type 2) Model
    • 13.96.2.6 The pixHep UCD (Urea Cycle Disorder) Models (ASS1, and OTC)
• 13.97 Pluristyx, Inc.
  • 13.97.1 FailSafe Cell System
  • 13.97.2 iACT Stealth Cells™
  • 13.97.3 Products
    • 13.97.3.1 PluriBank™
    • 13.97.3.2 PluriForm™ Kit
    • 13.97.3.3 PluriFreeze™ Cryopreservation System
    • 13.97.3.4 PluriKit™
  • 13.97.4 iPSC Generation
  • 13.97.5 Differentiated Cells
• 13.98 Porosome Therapeutics, Inc.
  • 13.98.1 iPSC Derived Beta Cell T1D Therapy
• 13.99 Quell Therapeutics Ltd
  • 13.99.1 Collaboration for iPSCs
• 13.100 Racthera Co., Ltd.
  • 13.100.1 Amchepry®
  • 13.100.2 Racthera’s Retinal Sheet (DSP-3077)
  • 13.100.3 Racthera's Retinal pigment epithelial cells (HLCR011)
  • 13.100.4 Racthera's Neural progenitor cells (SMP-0115)
• 13.101 Rege Nephro, Co., Ltd.
  • 13.101.1 RN-032
• 13.102 Repairon GmbH
  • 13.102.1 Technology
• 13.103 ReproCELL
  • 13.103.1 Services
  • 13.103.2 Product Offerings
  • 13.103.3 ReproCELL’s Clinical Pipelines
• 13.104 Res Nova Biologics
• 13.105 Ricoh Biosciences, Inc.
  • 13.105.1 Products
  • 13.105.2 Ricoh’s iPSC-related Services
  • 13.105.3 Ricoh’s Therapeutics Development Pipeline
• 13.106 Sampled
  • 13.106.1 Services
• 13.107 Sana Biotechnology
• 13.108 Sarcio, Inc.
  • 13.108.1 SEV-101
  • 13.108.2 SEVA-101
• 13.109 SCG Cell Therapy, Pte. Ltd.
• 13.110 SereNeuro Therapeutics
• 13.111 Shinobi Therapeutics
• 13.112 STEMCELL Technologies
  • 13.112.1 Services
• 13.113 StemCardia
  • 13.113.1 Core Product & Technology
• 13.114 StemSight
  • 13.114.1 StemSight’s Technology
• 13.115 Stemson Therapeutics
  • 13.115.1 KeyProduct & Service Portfolio
• 13.116 Stimuliver
• 13.117 Sumitomo Pharma
• 13.118 Synthego
  • 13.118.1 Core Capabilities
• 13.119 Telescope Therapeutics
  • 13.119.1 Core Cellular & Technology Platforms
• 13.120 Tempo Bioscience
  • 13.120.1 Products
• 13.121 Tenaya Therapeutics
  • 13.121.1 Drug Development Capability
  • 13.121.2 Disease Models
• 13.122 TGD Life Company Limited
  • 13.122.1 R&D Services
• 13.123 Thermo Fisher Scientific Inc.
  • 13.123.1 Key Contributions
• 13.124 Tolerance Bio
• 13.125 Trailhead Biosystems®
  • 13.125.1 HD-DoE (high-dimensional design-of-experiments) technology
  • 13.125.2 Trailhead’s Hematopoietic Progenitor Cells
  • 13.125.3 hiPSC-derived Dopaminergic Neurons
  • 13.125.4 hiPSC-derived Pancreatic Beta Cells
• 13.126 TreeFrog Therapeutics
  • 13.126.1 C-Stem™
• 13.127 Vanqua Bio
  • 13.127.1 Pipeline
• 13.128 Vascugen, Inc.
  • 13.128.1 Core Technology & Approach
• 13.129 VCCT Inc.
  • 13.129.1 VCCT’s Product Candidates
• 13.130 Vertex Pharmaceuticals
  • 13.130.1 Key iPSC-Based Products & Programs
• 13.131 Vivodyne
  • 13.131.1 Lab-Grown Organs
• 13.132 Yashraj Biotechnology, Ltd.
  • 13.132.1 Products
    • 13.132.1.1 Induced Pluripotent Stem Cell (iPSC) Lines
    • 13.132.1.2 iPSC-Derived Cardiomyocytes (YBLiCardio)
    • 13.132.1.3 iPSC-Derived Hepatocytes Like Cells (YBLiHepato)